Clinical Trials on Castration Resistant Prostate Cancer (CRPC)

Total 5680 results

Translational Research Center for Medical Innovation...

Completed

A Study to Determine Enzalutamide Long-term Safety and Efficacy After Anti-androgen Therapy for CRPC (DELC)

Castration Resistant Prostate Cancer (CRPC)
Astellas Pharma Europe B.V.
Medivation, Inc.

Completed

A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects

Healthy Subjects | Relative Bioavailability | Castration Resistant Prostate Cancer (CRPC) | MDV3100

Germany
Astellas Pharma Inc
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients

Prostate Cancer | Prostate Neoplasms | Castration Resistant Prostate Cancer (CRPC)

Japan
Pharmicell Co., Ltd.

Terminated

Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC-PC)

Castration Resistant Prostate Cancer, CRPC

Korea, Republic of
Nuvation Bio Inc.

Withdrawn

Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC

Prostate Cancer | Prostate Neoplasm | Cancer of the Prostate | Prostatic Cancer | Castrate Resistant Prostate Cancer | Cancer of Prostate | Castration Resistant Prostatic Cancer | Castration Resistant Prostatic Neoplasms

United States
Innocrin Pharmaceutical

Completed

A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer

Castration-resistant Prostate Cancer | CRPC

United States, Greece, Switzerland, United Kingdom
Innocrin Pharmaceutical

Completed

A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer

Castration-resistant Prostate Cancer | CRPC

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...

Withdrawn

A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer (Radium-223)

Prostate Cancer | Bone-only Metastatic Castration-Resistant Prostate Cancer (CRPC)

United States
Tiltan Pharma Ltd.

Unknown

Phase IIB Clinical Trial of Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC) (TLH-202)

Metastatic Castration Resistant Prostate Cancer (CRPC)

Israel
Astellas Pharma Europe B.V.
Medivation, Inc.

Completed

Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates

Castration Resistant Prostate Cancer (CRPC) | Pharmacokinetics of MDV3100

South Africa
Universität des Saarlandes

Recruiting

Prospective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study)

Prostate Cancer Metastatic | Advanced Prostate Carcinoma | Castration Resistant Prostatic Cancer

Germany
Bayer

Completed

Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo). (PHENIX)

Metastatic Castration-resistant Prostate Cancer (mCRPC)

United States
Janux Therapeutics

Recruiting

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

Prostate Cancer | Metastatic Castration-resistant Prostate Cancer | Castration Resistant Prostatic Cancer

United States, Australia
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Korea, Republic of, United States, Spain, France, Belgium, China, Taiwan, United Kingdom, Australia, Czechia, Hungary, Poland, Russian Federation
Constellation Pharmaceuticals

Active, not recruiting

ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer

Metastatic Castration Resistant Prostate Cancer (mCRPC)

United States
Avionco LLC

Completed

Safety, Tolerability and Pharmacokinetics of ONC1-0013B in Patients With Progressive Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Russian Federation
UNC Lineberger Comprehensive Cancer Center

Withdrawn

Exercise Intervention for Pts With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide

Metastatic Castration Resistant Prostate Cancer (mCRPC)

United States
Celcuity Inc

Recruiting

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer | Prostatic Neoplasms, Castration-Resistant | Genital Diseases, Male | Prostatic Disease | mCRPC (Metastatic Castration-resistant Prostate Cancer) | Urogenital Diseases, Male

United States, France, Spain, United Kingdom
Bayer

Completed

EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo) (EPIX)

Metastatic Castration Resistant Prostate Cancer (mCRPC)

United States
Jiangsu HengRui Medicine Co., Ltd.

Completed

Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer (mCRPC)

China
Memorial Sloan Kettering Cancer Center
Progenics Pharmaceuticals, Inc.

Completed

Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Prostate Cancer | Metastatic Castration-Resistant Prostate Cancer (mCRPC)

United States
University Hospital, Grenoble

Terminated

F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer (PRECHOL)

Castration-resistant Prostate Cancer

France
University of California, San Francisco
Merck Sharp & Dohme LLC

Completed

Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects

Metastatic Prostate Cancer | Castration Resistant Prostatic Cancer

United States
Astellas Pharma Inc
Pfizer

Completed

Long-Term Specified Drug Use-Results Survey for Xtandi Capsule

Castration-resistant Prostate Cancer

Japan
BAMF Health

Recruiting

Use of SPECT-CT for Comparison of Dosimetry Methods in PSMA-targeted Radioligand Therapy (SPECTacular Study) (SPECTacular)

Metastatic Castration-resistant Prostate Cancer

United States
Centre Francois Baclesse
National Cancer Institute, France

Completed

Impact of New Generation Hormono-therapy on Cognitive Functions in Elderly Patients Treated for a Metastatic Prostate Cancer (COG-PRO)

Metastatic Castration-resistant Prostate Cancer (CRPCa)

France
BeiGene

Terminated

Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency

Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Homologous Recombination Deficiency (HRD)

United States, Australia, Puerto Rico, Spain
Astellas Pharma Inc
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100

Castration-Resistant Prostate Cancer (CRPC)

United States, Moldova, Republic of, South Africa
Massachusetts General Hospital
Bayer

Completed

A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer

Prostate Cancer | Castration-resistant Prostate Cancer | Castration-resistant Prostate Cancer Metastatic to Bone

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets

Metastatic Castration-resistant Prostate Cancer

China
Hinova Pharmaceuticals Inc.

Completed

A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics

Metastatic Castration Resistant Prostate Cancer

China
Radboud University Medical Center
Astellas Pharma Europe B.V.

Completed

Personalizing Enzalutamide Therapy by Understanding the Relation Between Tumor mRNAs, miRNAs and Treatment Response (ILUMINATE)

Metastatic Castration Resistant Prostate Cancer

Netherlands
Rigshospitalet, Denmark

Completed

Bone Marrow Suppression and Recovery During Radionuclide Treatment

Castration-resistant Prostate Cancer

Denmark
University Health Network, Toronto

Completed

Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA (BARRIER-P)

Castration-resistant Prostate Cancer

Canada
Pfizer

Completed

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

Metastatic Castration Resistant Prostate Cancer (mCRPC) | Metastatic Castration Sensitive Prostate Cancer (mCSPC)

Finland
Sun Yat-sen University

Recruiting

Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi)

Metastatic Castration-resistant Prostate Cancer

China
Syneos Health
Antares Pharma Inc.

Withdrawn

Phase 1 Study of ATRS-2002 in Healthy Male Adults

Metastatic Castration-resistant Prostate Cancer
MANA RBM
Bayer; Tulane University; Barbara Ann Karmanos Cancer Institute; Carolina Urologic...

Terminated

A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients (ESCALATE)

Metastatic Castration-resistant Prostate Cancer

United States
Radboud University Medical Center
Janssen-Cilag Ltd.

Completed

Optimizing Abiraterone Therapy (OPTIMUM)

Metastatic Castration Resistant Prostate Cancer

Netherlands
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Recruiting

Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer (FASN)

Prostate Cancer | Refractory Cancer | Castration Resistant Prostatic Cancer

United States
Veru Inc.

Terminated

Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent (VERACITY)

Metastatic Castration-resistant Prostate Cancer | Androgen Resistant Prostatic Cancer

United States
Pengyuan Liu

Recruiting

Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer (CRPC)

China
The First Affiliated Hospital of Xiamen University

Recruiting

Clinical Evaluation of 177Lu-DansyI-PSMA (LNC1011) in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer, mCRPC

China
Peter MacCallum Cancer Centre, Australia

Recruiting

Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men With Metastatic Castration-Resistant Prostate Cancer (AlphaBet)

Prostate Cancer | Metastatic Castration-resistant Prostate Cancer | mCRPC

Australia
British Columbia Cancer Agency

Recruiting

PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA (PROTRACT)

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Canada
AstraZeneca

Completed

An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer

Prostate Cancer | Metastatic Castration-Resistant Prostate Cancer (mCRPC)

United States
Advanced Accelerator Applications

No longer available

177Lu-PSMA-617 Managed Access Program for mCRPC Patients

Metastatic Castration-resistant Prostate Cancer (mCRPC)
Rohan Garje
Janssen Scientific Affairs, LLC

Not yet recruiting

177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer (LUNAAR)

Castration-resistant Prostate Cancer | Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
Inmune Bio, Inc.

Recruiting

Study of INKmune in Patients With mCRPC (CaRe Prostate) (CaRe)

Cancer | Metastatic Castration-resistant Prostate Cancer | mCRPC

United States
Sumitomo Pharma Switzerland GmbH

Active, not recruiting

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Sensitive Prostate Cancer | Non-Metastatic Castration-Resistant Prostate Cancer

United States

Clinical Trials on Castration Resistant Prostate Cancer (CRPC)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations